Skip to main content

Facilitating Collaborations to Develop Combination Investigational Cancer Therapies Workshop Summary (2012) / Chapter Skim
Currently Skimming:

10 Wrapping Up
Pages 73-76

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 73...
... In the preclinical arena, participants suggested more effort and funding to develop animal models in which to test investigational drug combinations and their mechanisms of action and pharmacokinetics, as well as resistance mechanisms. These animal models could entail tumor explants or be genetically engineered to develop tumors with the molecular defects commonly seen in human tumors.
Read the entire page →
From page 74...
... Researchers need to explore more creative innovations in the approach to dosing and scheduling to avoid toxicity and improve efficacy, several participants suggested. Agents could be used intermittently or sequenced in a manner that makes sense from a biological, mechanistic perspective.
Read the entire page →
From page 75...
... Safe harbors for companies and institutions, such as FNIH and the CEO Roundtable on Cancer Life Sciences Consortium, have proven helpful in negotiating collaborations and managing the patents and other intellectual property rights that result from such collaborations. A safe harbor to distribute study drugs to investigators, or to do preliminary clinical testing of combinations, might substantially further development of combination cancer therapies, many participants stressed.
Read the entire page →
From page 76...
... Several scientific tools to aid cancer combination therapy development are available in the public domain, including GSK's epigenetic toolbox and preclinical data, NCI's mechanism-of-action assays and preclinical models for combinations, as well as the investigational agents that NCI makes available for preclinical testing. Several participants stressed the importance of doing whatever it takes to facilitate collaboration in the development of combination investi gational cancer therapies.
Read the entire page →

Key Terms

  • clinical testing
  • combination cancer
  • animal models
  • patient selection
  • combination therapies

  • participants stressed
  • cancer combination
  • legal issues
  • preclinical data
  • tumor cell

  • legal negotiations
  • molecular defects
  • resistance mechanisms
  • cell lines
  • share patient

  • treatment effectiveness
  • facilitate collaboration
  • putting pressure
  • single agents
  • pose barriers

  • adaptive trial
  • commonly seen
  • key decision
  • entail tumor
  • clinical studies

  • drug combinations
  • tigational agents
  • assess effectiveness
  • cause toxicity
  • human tumors


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.